Question special
Lead Moderator

One of the central themes of this discussion has been that additional clinical trials in heterogeneous populations of critically-ill patients are unlikely to yield useful results. Instead, using clinical and/or biologic factors to identify more homogeneous subgroups of critically-ill patients for investigation may be a more fruitful approach (doi: 10.1164/rccm.201604-0697ED).

To date, there remains no specific therapy for patients with sepsis. How will the Sepsis III definitions help facilitate a more nuanced approach to sepsis clinical trial design? What do you think are the next steps towards precision medicine in sepsis?